Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Massive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review

dc.contributor.authorNadal Serra, Alfons
dc.contributor.authorCardesa García, Antonio
dc.contributor.authorAgaimy, Abbas
dc.contributor.authorAlmangush, Alhadi
dc.contributor.authorFranchi, Alessandro
dc.contributor.authorHellquist, Henrik
dc.contributor.authorLeivo, Ilmo
dc.contributor.authorZidar, Nina
dc.contributor.authorFerlito, Alfio
dc.date.accessioned2026-03-13T16:51:19Z
dc.date.available2026-03-13T16:51:19Z
dc.date.issued2024-11-29
dc.date.updated2026-03-13T16:51:25Z
dc.description.abstractHead and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and is a cause of significant mortality and morbidity. The epidemiology of this cancer varies worldwide due to either genetic differences in populations or differences in carcinogen exposure. The application of massive parallel sequencing-based techniques in HNSCC should provide a helpful understanding of the genetic alterations that eventually lead to HNSCC development and progression, and ideally, could be used for personalized therapy. In this review, the reader will find an overview of the mutational profile of conventional HNSCC according to published results on massive parallel sequencing data that confirm the pivotal role of TP53 and the frequent involvement of CDKN2A and PIK3CA. The reader will also find a more detailed description of the genes, such as NOTCH1 and FBXW7, that were not identified in HNSCCs before the development of these techniques, the differences that can be site-specific, such as the different mutational signatures that indicate specific carcinogens for various subsites of the head and neck, and finally, the actionability of these findings that should allow more personalized therapy for patients.
dc.format.extent12 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec757383
dc.identifier.issn0945-6317
dc.identifier.pmid39613893
dc.identifier.urihttps://hdl.handle.net/2445/228087
dc.language.isoeng
dc.publisherSpringer Verlag
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1007/s00428-024-03987-2
dc.relation.ispartofVirchows Archiv. European Journal of Pathology, 2024, vol. 485, num. 6, p. 965-976
dc.relation.urihttps://doi.org/10.1007/s00428-024-03987-2
dc.rightscc-by (c) Nadal Serra, Alfons et al., 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceArticles publicats en revistes (Fonaments Clínics)
dc.subject.classificationCàncer de cap
dc.subject.classificationCàncer de coll
dc.subject.classificationCèl·lules canceroses
dc.subject.otherHead cancer
dc.subject.otherNeck cancer
dc.subject.otherCancer cells
dc.titleMassive parallel sequencing of head and neck conventional squamous cell carcinomas: A comprehensive review
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
890219.pdf
Mida:
1.33 MB
Format:
Adobe Portable Document Format